Drug Profile
MT 201 - Meiji Dairies Corporation
Alternative Names: TAK 201Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Meiji Dairies Corporation
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Allergic conjunctivitis; Seasonal allergic rhinitis
Most Recent Events
- 04 Aug 2005 Takeda has terminated its licence for MT 201 in Japan and other countries
- 30 Apr 2005 Phase-III clinical trials in Allergic conjunctivitis in Japan (unspecified route)
- 30 Apr 2005 Phase-III clinical trials in Seasonal allergic rhinitis in Japan (unspecified route)